key: cord-0909832-ik1058f1
authors: Magallanes‐Garza, Gerardo I.; Valdez‐Alatorre, Carolina; Dávila‐González, Daniel; Martínez‐Reséndez, Michel F.; Sánchez‐Salazar, Sergio S.; Castilleja‐Leal, Fernando; Cardona‐Huerta, Servando
title: Rapid improvement of a critically ill obstetric patient with SARS‐CoV‐2 infection after administration of convalescent plasma
date: 2020-12-29
journal: Int J Gynaecol Obstet
DOI: 10.1002/ijgo.13467
sha: 18c3f1f8f5062fb0a9d19c1f57b5265304cf9f6c
doc_id: 909832
cord_uid: ik1058f1

SARS-CoV-2 (COVID-19) infection in pregnancy increases the likelihood of hospitalization, admission to intensive care, and receipt of mechanical ventilation as compared with nonpregnancy [1]. On June, 21, 2020, a 33-year-old pregnant woman (274 gestational weeks) with SARS-CoV-2 infection presented to Hospital San José Tec Salud, Monterrey, México, with respiratory distress and oxygen saturation below 90% (room oxygen). She had developed fever, asthenia, adynamia, myalgia, dry cough, anosmia, and diarrhea 7 days prior to admission. Her past medical history was significant for smoking, which she had stopped at 4 gestational weeks.

with SARS-CoV-2 infection presented to Hospital San José Tec Salud, Monterrey, México, with respiratory distress and oxygen saturation below 90% (room oxygen). She had developed fever, asthenia, adynamia, myalgia, dry cough, anosmia, and diarrhea 7 days prior to admission. Her past medical history was significant for smoking, which she had stopped at 4 weeks of gestation.

On admission, the woman was treated with oxygen therapy (8 L/ min) via a nasal cannula; chest X-ray showed bilateral interstitial infiltrates. Laboratory data revealed leukopenia with lymphopenia, raised interleukin-6 and C-reactive protein, and compensated respiratory alkalosis (Fig. 1) .

Therapy was initiated with enoxaparin (60 mg), azithromycin (250 mg), ceftaroline (600 mg), lopinavir/ritonavir (400 mg/100 mg), methylprednisolone (40 mg), and supportive care (antipyretics, analgesics, fluids, and nutrition). On hospital day 2 (HD2), saturation decreased and chest X-ray showed an extension and worsening density of interstitial infiltrates. On HD3, the woman was intubated and placed on mechanical ventilation; intermittent pressure support with intravenous ephedrine was provided as needed owing to intermittent periods of hypotension and bradycardia. Continuous fetal heart rate monitoring was non-reassuring. Serum IgG against SARS-Cov-2 was undetectable. Despite medical treatment, her condition continued to deteriorate. A multidisciplinary team discussed the case and the possible therapeutic interventions. We sent a request to the hospital Bioethics Committee for compassionate use of convalescent plasma. The request was approved. Methylprednisolone was discontinued and prenatal corticosteroid therapy was initiated.

The treatment plan and options were discussed with the patient's legally authorized representative who consented to proceed with the administration of convalescent plasma. 

The authors have no conflicts of interest.

The patient in this case study was supervised by GM, CV, SC, MM, JC, and SS. DD and SC were involved in recruitment of the convalescent plasma donor. CV, GM, and DD wrote the final manuscript.

Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United States

Coronavirus disease 2019 (COVID-19) pandemic and pregnancy

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report. Case Rep Women's Heallth

Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review